Select your country
Select a country to go to the website of the respective STADA sales company.
Saudi Arabia (1)
The Phillippines (1)
United Arab Emirates (1)
STADA – The Trusted Partner in Healthcare
Acting as a trusted partner throughout the medicines supply chain is central to delivering on STADA’s core purpose: Caring for People’s Health.
From product development, ingredient sourcing, manufacturing and packaging through to regulatory approval, distribution and marketing, STADA augments its in-house expertise and capabilities by collaborating closely with strategic partners who bring unique perspectives, capacities and competencies.
Leveraging the capabilities of thousands of partners enables STADA to bring a broad, unique portfolio of Consumer Healthcare products, Specialty Pharmaceuticals and Generics to patients and healthcare professionals around the world.
Agreements to distribute and market Sanofi Consumer Healthcare’s entire portfolio in 20 European countries as well as a further 10 countries in the Eurasia region
STADA and Sanofi strike consumer healthcare distribution agreement in selected countries in Europe | STADA
These followed a transaction in which STADA acquired 16 well-established consumer healthcare brands from Sanofi in Europe
STADA further grows European Consumer Healthcare portfolio by acquiring 16 well-established brands from Sanofi | STADA
Transaction with GlaxoSmithKline (GSK) to acquire 15 well-established consumer healthcare brands across more than 40 countries, following a previous deal for five non-prescription skincare brands
STADA becomes a major Consumer Healthcare player by acquiring 15 well-established GSK brands | STADA
Strategic partnership with Iceland’s Alvotech to expand patient access to adalimumab, a biologic treatment for autoimmune conditions, in Europe
Alvotech and STADA Broaden Access to Adalimumab Biosimilar | STADA
as well as to submit a marketing authorization application for the immunology agent ustekinumab EMA Confirms Acceptance of Application for AVT04 | STADA
Collaborating with Sweden’s Calliditas to obtain the first approval in the European Union for a treatment for the rare kidney disease immunoglobulin A nephropathy (IgAN)
Launching first medicine for treating rare kidney disease | STADA
We partner with mAbxience to expand our specialty oncology portfolio with the launch of biosimilar bevacizumab. The cancer treatment is available to oncologists and their patients in Germany and the Netherlands, with launches in other European countries to follow.
STADA strengthens oncology offering by launching bevacizumab biosimilar | STADA
We collaborate with Richter-Helm-BioTec GmbH & Co.KG on the in-icensing teriparatide for the treatment of osteoporosis and thereby expanding our biosimilar portfolio. Teriparatide-Biosimilar for treatment of osteoporosis launched in 24 countries | STADA
Extension of a strategic partnership with Adalvo to obtain commercial rights in Europe to five additional active ingredients in therapeutic categories including oncology and diabetes
Adalvo and STADA extend their strategic partnership | STADA